Skip to main content
ADHDnotepad
Medication guide

Xaggitin XL

Methylphenidate hydrochloride (prolonged-release)

StimulantOnce daily12-hour coverageSchedule 2 CD
Reading time: about 6 minutesLast reviewed: May 2026Download the one-page summary (PDF)
Section 1

Overview

Medication class

Xaggitin XL is a 12-hour prolonged-release methylphenidate tablet that is bioequivalent to Concerta XL (the reference product) per SPS August 2025. Its 25:75 IR:MR ratio is slightly higher in immediate-release fraction than Concerta XL (22:78), but SPS confirms the two are bioequivalent and interchangeable within the group during supply disruption at the same dose. MHRA guidance (September 2022): Methylphenidate MR products must be prescribed and dispensed by brand name. Even within the bioequivalence group, do not switch brands without clinical guidance.

When it's prescribed

Prescribed for ADHD in children aged 6 and over and adults, per NICE NG87. Must be prescribed and dispensed by brand name (MHRA guidance, September 2022).

Typical duration

Up to 12 hours

Available strengths

18 mg, 27 mg, 36 mg, 54 mg. Maximum: 54 mg/day (children); up to 72 mg/day adults (per SmPC)

Key advantages

  • 12-hour duration: full working-day coverage from a single morning tablet
  • Not pH-dependent: compatible with PPIs and antacids
  • No food requirement
  • Part of the largest UK bioequivalence group: supply disruption management options available within the group

Key cautions

  • Tablet must be swallowed whole: no crushing, cutting, or opening
  • Lower first-peak than capsule brands: effect builds gradually through the morning
  • You may see a tablet shell in your stools; this is normal and means the medication has been absorbed correctly
Section 2

How it works

Methylphenidate blocks the brain's recycling transporters for dopamine and noradrenaline: keeping them active longer in the synapse. This helps with attention, motivation, and impulse control in ADHD.

Xaggitin XL is a prolonged-release tablet with a 25:75 IR:MR ratio. This means 25% of the dose releases promptly in the first 1–2 hours, with the remaining 75% released gradually over the following hours: providing therapeutic coverage for up to 12 hours from a single morning dose.

The release profile produces an ascending plasma curve through the day: a moderate initial effect in the morning, building to a sustained level through the afternoon. The tablet must remain intact for this mechanism to work correctly. Crushing or breaking it releases the full dose at once.

Xaggitin XL is not pH-dependent: compatible with acid-suppression medications.

Section 3

How to take it

When to take it

Once in the morning. Up to 12 hours' duration: take before 9am to avoid it being active at bedtime.

With or without food

Either is fine.

Swallow whole

Take with a full glass of water. Do not crush, break, chew, or cut the tablet. The prolonged-release mechanism only works as an intact tablet.

Missed dose

If still morning, take as soon as you remember. If mid-afternoon, skip it. Never double up.

Alcohol

Avoid entirely. Risk of dose-dumping and ethylphenidate formation.

Section 4

What to expect: week by week

Days 1–7

Adjustment

Appetite dips (especially afternoons); mild headache (usually dehydration); possibly feeling more alert. Most settle by week 2.

Weeks 2–4

Settling in

Most early side effects reduce. Coverage builds gradually: some people notice the effect strengthens through the morning. This is how prolonged-release tablets are designed to work.

Weeks 4–8

Optimising

Titration in 18 mg increments. The goal is the lowest dose that manages symptoms well for long enough, with the fewest side effects.

3 Months+

Maintenance

Reviews every 6 months. BP, HR, and weight checked at each visit.

Section 5

Side effects & what helps

All expanded by default: tap a category to collapse it. Most of these ease in the first 1–2 weeks.

Reduced appetite; weight loss (long-term)

Very common

What helps

Eat breakfast before your dose. Appetite usually returns in the evening.

Difficulty sleeping if taken late

Very common

What helps

Take before 9am. Discuss with prescriber if still disrupted at 4 weeks.

Increased HR and BP; palpitations

Common

What helps

Monitored at every review. Contact prescriber if resting HR consistently above 100 bpm.

Anxiety, irritability, low mood

Common

What helps

Tell your prescriber if persistent.

Suicidal thoughts

Uncommon

What helps

Contact prescriber or crisis support immediately.

Psychosis symptoms; mania

Uncommon/Rare

What helps

Stop and seek urgent review.

Headache

Very common

What helps

Usually settles by week 2. Drink more water.

Dizziness, tremor

Common

What helps

Don't drive while dizzy.

Tics

Rare

What helps

Contact your prescriber.

Nausea, dry mouth, sweating, hair thinning, teeth grinding

Common

What helps

Mention at your next review if troublesome.

Priapism (painful erection more than 2 hours)

Rare: medical emergency

What helps

Attend A&E immediately.

Section 6

When to seek help

No action

Expected: mention at next review

Common in the first few weeks: no action usually needed

  • Mild appetite reduction
  • Mild headache weeks 1–2
  • Dry mouth
  • Mild sleep difficulty
  • Mild irritability improving
Contact prescriber

Contact your prescriber within a few days

Not urgent: but worth discussing at your next review

  • Resting HR >100 bpm
  • BP persistently raised
  • Headaches beyond 2 weeks
  • Mood not settling at 4 weeks
  • Sleep severely disrupted beyond 4 weeks
  • Significant weight loss
  • Tics
  • Blurred vision; Raynaud's
Urgent

Contact prescriber or 111 today

Do not wait for a routine appointment

  • Resting HR >120 bpm
  • Fainting
  • Suicidal thoughts
  • Hallucinations/psychosis
  • Priapism
  • Severe allergic reaction
  • New mania

What you can safely try while waiting for a review

    Section 7

    Frequently asked questions

    How is Xaggitin XL different from Concerta XL?

    Both are 12-hour prolonged-release tablets. Xaggitin XL has a slightly higher immediate-release fraction (25% vs. 22% for Concerta XL), but SPS confirms the two are bioequivalent. The clinical effect and duration are equivalent. The manufacturers differ. Your prescriber or pharmacist may have chosen Xaggitin XL for availability or formulary reasons.

    My pharmacy gave me a different brand. Is that okay?

    Not without speaking to your prescriber first. Even though Xaggitin XL is part of the tablet bioequivalence group, do not simply accept a different brand: confirm with your prescriber first.

    Does it interact with omeprazole or antacids?

    No: Xaggitin XL is not pH-dependent. Compatible with PPIs and antacids.

    Can I drink alcohol?

    Avoid entirely: risk of dose-dumping and ethylphenidate formation.

    I'm pregnant or breastfeeding: what do I need to know?

    Pregnancy: Speak to your prescriber before making any changes (BUMPS/UKTIS January 2023). Do not stop without advice. Breastfeeding: Methylphenidate is the stimulant of choice during breastfeeding (BfN April 2025). Very low milk levels. No need to stop breastfeeding. Monitor baby.

    Section 8

    Ask your prescriber

    Questions worth raising at your next review. You don't need to cover all of them: pick the ones that feel most relevant.

    • Why Xaggitin XL: rather than Concerta XL or another brand?
    • What dose are we starting at, and what is the maximum?
    • What if my pharmacy can't get Xaggitin XL?
    • Which side effects should I call you about?
    • If Xaggitin XL doesn't work well enough, what would we try next?
    Section 9

    For GPs & clinicians

    For GPs and clinicians

    Xaggitin XL (Martindale Pharma): prolonged-release tablet; 25:75 IR:MR; ascending 12h profile. Not pH-dependent. No food requirement. Bioequivalent to Concerta XL per SPS August 2025.

    Affenid XL, Atenza XL, Concerta XL, Delmosart, Matoride XL, Xaggitin XL, Xenidate XL: interchangeable within group at same dose/quantity during supply disruption.

    Not formally licensed for adults (BNF). Under specialist direction per NICE NG87. SmPC permits up to 72 mg/day for adults. BP and HR at baseline, dose changes, minimum every 6 months. Weight each review.

    MAOIs (contraindicated); alcohol (ethylphenidate formation, dose-dumping); antihypertensives (reduced efficacy); coumarin anticoagulants (monitor INR).

    This guide is written for educational purposes and does not constitute medical advice. Always follow the guidance of your prescriber or pharmacist. If you have concerns about your medication, contact your clinical team.